Director, Field Medical

Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency. As a critical member of Lyell's inaugural U.S. Field Medical Team, the Director, Field Medical will serve as a field-based subject matter expert on cellular therapy for the external health care professional (HCP) community and internal partners. Reporting directly to the Senior Director, Field Medical, this high-performing field medical professional will be responsible for driving strategic regional external engagement, deep therapeutic expertise, pivotal clinical trial support, and advanced insight generation across hematologic and solid tumors—particularly within cellular therapy to establish Lyell as the partner of choice in the rapidly evolving cellular therapy landscape. This role is expected to model AI-fluency for field medical — leveraging emerging tools for scientific synthesis, insight generation, and engagement planning to operate with the speed and impact of a team. This role will initially operate as an individual contributor with a defined pathway to people management. As Lyell's field team expands, the Director, Field Medical will assume responsibility for recruiting, coaching, and leading a team of MSLs within their region. KEY ROLE AND RESPONSIBILITIES Strategic Territory Ownership & Team Foundation Design and execute comprehensive, insight-driven regional territory plan aligned with Medical Affairs strategy through sophisticated mapping and engagement of HCPs, cellular therapy treatment centers, CAR-T referring networks, disease-area influencers, and institutional decision makers. Leverage advanced knowledge of the CAR-T ecosystem — augmented by AI-powered landscape tools, literature synthesis platforms, and digital signal monitoring — to anticipate scientific, clinical, and operational needs across the territory. Apply strategic acumen and innovation to shape regional medical priorities and tactics. Serve as foundational member of inaugural field medical team, contributing to creation of standardized field medical processes, external and internal resources, and mentorship and supervision of future MSL hires. Prepare for future team leadership by contributing to MSL hiring, onboarding frameworks, and performance management processes in partnership with the Senior Director, Field Medical. Scientific Exchange & Stakeholder Engagement Function as the regional scientific expert in cellular immunotherapy, delivering high-impact, fair-balanced scientific exchange tailored to the needs of: Key Opinion Leaders (KOLs) Academic investigators Transplant a